EODData

MEMBERSHIP REGISTER LOG IN

FRA, 36X: ASCENTAGE PHARM. DL-0001

03 Nov 2025
LAST:

7.500

CHANGE:
 0.15		OPEN:
7.500		HIGH:
7.500		ASK:
0.000		VOLUME:
2.1K
CHG(%):
2.04		PREV:
7.350		LOW:
7.500		BID:
0.000		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
03 Nov 257.5007.5007.5007.5002.1K
31 Oct 257.3507.3507.3507.3502.1K
30 Oct 257.2507.2507.1507.1502.1K
29 Oct 256.9506.9506.9506.95073
28 Oct 257.2507.2507.2507.25073
27 Oct 257.4007.4007.1007.10073
24 Oct 257.4507.5007.4507.45073
23 Oct 257.2007.2507.2007.20073
22 Oct 257.4007.4507.4007.45073
21 Oct 257.5507.5507.5507.55073

COMPANY PROFILE

Name:ASCENTAGE PHARM. DL-0001
About:Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company's primary product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1 mutants, including those with the T315I mutation. It also develops APG-2575, an oral administered Bcl-2 selective inhibitor for hematologic malignancies and solid tumors; APG-115, an oral small molecule inhibitor of the MDM2-p53 protein-protein interactions to treat solid tumors and hematological malignancies; and APG-1252, a small molecule drug to restore apoptosis through dual inhibition of the Bcl-2 and Bcl-xL proteins for the treatment of small-cell lung cancer, non-small cell lung cancer, neuroendocrine tumor, and non-Hodgkin's lymphoma. In addition, the company is developing APG-1387, a small-molecule inhibitor of apoptosis proteins for advanced solid tumors and chronic HBV infection; APG-2449, an oral inhibitor of FAK, ROS1, and ALK kinases; APG-5918, an orally available and selective embryonic ectoderm development inhibitor. In addition, it is involved in medical research and development; clinical development; clinical trials operations; venture capital investment; rental of buildings; and provision of science and technology promotion services. The company has collaboration relationships with biotechnology and pharmaceutical companies; and research institutions. Ascentage Pharma Group International was founded in 2009 and is headquartered in Suzhou, China.
Sector:Healthcare
Industry:Biotechnology
Address:Suzhou Industrial Park, Suzhou, China, 215000
Website:https://www.ascentage.cn
ISIN:KYG0519B1023

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

Trailing P/E:-5.60 
Price to Sales:7.00 
Price to Book:3.79 
Profit Margin:-2.97 
Operating Margin:-2.37 
Return on Assets:-0.23 
Return on Equity:-1.60 
Revenue:47.58M 
Shares:371.85M 
Market Cap:2.789B 

TECHNICAL INDICATORS

MA5:7.243.6%
MA10:7.302.8%
MA20:7.571.0%
MA50:8.2510.0%
MA100:8.2510.0%
MA200:6.5015.5%
STO9:100.00 
STO14:55.00
RSI14:51.61
WPR14:-45.00
MTM14:-0.25
ROC14:-0.03 
ATR:0.25 
Week High:7.500.0%
Week Low:6.957.9%
Month High:8.5514.0%
Month Low:6.9515.5%
Year High:10.0033.3%
Year Low:3.74100.6%
Volatility:37.75